Vanderbilt-Ingram Cancer Center Launches Phase 1 Clinical Trial for Novel PET Imaging Agent

Strategic Insights -

A Phase 1 interventional clinical trial, led by principal investigator Eben Rosenthal, MD, has been initiated at the Vanderbilt-Ingram Cancer Center to evaluate the safety, tolerability, and diagnostic performance of a novel PET imaging agent, [18F]NOTA-ABY030, in patients with head and neck squamous cell carcinoma (HNSCC). The trial aims to enroll 60 participants from the USA and will assess the investigational agent's safety profile, radiation dosimetry, and diagnostic accuracy compared to conventional imaging modalities. The study's findings may lead to improved staging accuracy and reduced unnecessary biopsies in patients with HNSCC, ultimately streamlining treatment decisions.

Key Takeaways:

  • The trial is a Phase 1 interventional clinical trial to evaluate the safety, tolerability, and diagnostic performance of [18F]NOTA-ABY030 in patients with HNSCC.
  • The principal investigator of the trial is Eben Rosenthal, MD, at the Vanderbilt-Ingram Cancer Center.
  • The study aims to enroll 60 participants from the USA and will assess the investigational agent's safety profile, radiation dosimetry, and diagnostic accuracy.
  • The trial will compare the sensitivity and specificity of [18F]NOTA-ABY030 to conventional imaging modalities such as MRI, CT, and [18F]FDG-PET/CT.
  • The study's findings may lead to improved staging accuracy and reduced unnecessary biopsies in patients with HNSCC.
  • The trial's purpose is to evaluate the novel PET imaging agent's diagnostic performance and safety profile in patients with HNSCC.

Statistics:

  • 60 participants will be enrolled in the trial.
  • The trial will be conducted at the Vanderbilt-Ingram Cancer Center.
  • The investigational agent is a novel PET imaging agent, [18F]NOTA-ABY030.
  • The study will compare the sensitivity and specificity of [18F]NOTA-ABY030 to conventional imaging modalities such as MRI, CT, and [18F]FDG-PET/CT.
  • The trial's purpose is to evaluate the novel PET imaging agent's diagnostic performance and safety profile in patients with HNSCC.

Sources:

  • ClinicalTrials.gov [NCT07217028]